source
- FDA pushes back decision on Capricor’s Duchenne cell therapy, GSK clears hepatitis B drug in JapanThe U.S. Food and Drug Administration has extended its review of Capricor Therapeutics' experimental Duchenne muscular dystrophy cell therapy, deramiocel. The agency moved its decision deadline fro…
- Moderna’s melanoma vaccine trial success sparks $45 billion market value surgeModerna’s shares jumped more than 170% after the company announced that its experimental melanoma vaccine, intismeran, met its primary goals in a Phase 3 trial. The surge added roughly $45 billion…